Hims & Hers Health, Inc. (HIMS) Expands Global Footprint With Eucalyptus Acquisition

Hims & Hers Health, Inc. (NYSE:HIMS) is among the 7 Oversold Pharma Stocks to Buy Now.

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the most oversold stocks.

HIMS declared on February 19, 2026, that it has finalized a deal to purchase Eucalyptus for a maximum of $1.15 billion, subject to usual adjustments. The remaining consideration will consist of guaranteed deferred payments over the next 18 months and subsequent earnouts linked to certain financial milestones through early 2029. The business will pay about $240 million in cash upon closing.

Hims & Hers Health, Inc. (NYSE:HIMS) anticipates using current cash and future U.S. operating cash flows to finance the agreement, and it may choose to fund the majority of the deferred and earnout amounts in cash or shares. It is expected that the transaction will close in the middle of 2026, subject to regulatory approvals and other standard conditions.

In other news, on the same day, HIMS moved forward with plans to sell a $49 oral semaglutide weight-loss pill but quickly reversed course after facing immediate backlash from Novo Nordisk (NVO) and U.S. regulators. Within two days of the announcement, the company pulled the offering after the FDA commissioner characterized such products as “illegal copycats.” The abrupt retreat has raised questions about the company’s future growth strategy following the failed launch.

Hims & Hers Health, Inc. (NYSE:HIMS) is a direct-to-consumer telehealth company that provides prescription medications and wellness products in areas such as dermatology, mental health, sexual health, and primary care through its online platform.

While we acknowledge the potential of HIMS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Unstoppable Dividend Stocks to Buy According to Analysts and Dividend Champions, Contenders and Challengers list: 15 Highest Yielding Stocks.

Disclosure: None.